Brought to you by 
NuPathe privately raises $28mm
27 Sep 2012
Executive Summary
NuPathe Inc. (neurological drug delivery) has raised $28mm by selling 14mm units at $2 to first-time and returning institutional and individual investors led by Quaker Bioventures II and Safeguard Delaware. The company says the funds will sustain operations for one year, including gaining approval for its lead candidate, the transdermal migraine patch NP101 (sumatriptan), securing a partner, and pre-launch preparations.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
- Transdermal
-
Drug Delivery
-
Medical Devices
- Implantable Devices
Deal Status
- Final
Deal Type
-
Financing
- Other
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
NuPathe privately raises $28mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice